Invention Grant
- Patent Title: Cyclic peptide immunomodulators
-
Application No.: US16753666Application Date: 2018-10-02
-
Publication No.: US11492375B2Publication Date: 2022-11-08
- Inventor: Michael Matthew Miller, II , Martin Patrick Allen , Ling Li
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2018/053871 WO 20181002
- International Announcement: WO2019/070643 WO 20190411
- Main IPC: C07K7/50
- IPC: C07K7/50 ; A61K38/12 ; C07K7/56 ; A61K38/00
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Public/Granted literature
- US20200291069A1 IMMUNOMODULATORS Public/Granted day:2020-09-17
Information query
